Compared with the control group (shRNA-NC), the number of colon cancer cell clones in the shRNA-LIMK1 treatment group was significantly reduced, with a statistically significant difference (Figure 3(c)). This evidence concerns the gene LIMK1 and malignant colon neoplasm.